RxDoctor Payments Data

Alexander Ross, MD

Cardiovascular Disease · Washington, DCNPI 1831457936

Payments from drug & device makers

What this record shows

5 manufacturers reported payments, led by Intuitive Surgical at 57.9% of the total. Reporting peaked in 2022 at $1,015 and has fallen 85.2% since, to $150 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in DC, where the typical reported total is $1,279.

$1,579in general payments, 2019–2025

Across 14 payments — averaging $112.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$915
  • Heartflow, Inc.$498
  • E.r. Squibb & Sons, L.L.C.$128
  • Bracco Diagnostics Inc.$22
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16

What the payments were for

  • Travel & lodging$91558%
  • Food & beverage$66442%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,579 in reported general payments places this provider in the 50th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$255,886
Medicare patients
1,133
Services billed
18,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin250$349,025
EliquisApixaban220$340,389
XareltoRivaroxaban145$179,230
EntrestoSacubitril/Valsartan66$102,937
Repatha SureclickEvolocumab74$78,892
FarxigaDapagliflozin Propanediol30$33,394
Telmisartan380$11,433
Rosuvastatin Calcium866$11,404
Ezetimibe474$10,886
Nebivolol Hcl137$10,576
Eplerenone66$7,074
PradaxaDabigatran Etexilate Mesylate22$5,643
Metoprolol Succinate372$5,044
Carvedilol475$4,599
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,717

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →